Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 52

Sponsor: Medical University of Graz

Summary

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

Eligibility Criteria

Inclusion Criteria: * • Liver cirrhosis (clinical/radiological/histological diagnosis) * Indication for LOLA use (covert or over hepatic encephalopathy, Grad 0-2)) * Written informed consent * Age 18 -100 years Exclusion Criteria: * • Allergy to LOLA or its constituents, or to medications with a similar chemical structure (oral nutritional supplements are allowed when stable \>/= 8 weeks before and during the study) * Recent (\3mg/dl * Hepatocellular carcinoma BCLC D under best supportive care * Inability to give informed consent * Pregnancy or breastfeeding * Participation in another interventional trial within the last 30 days

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05737030). StuddyBuddy aggregates publicly available trial information.